Polysorbate 80
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
- Polysorbate 80
- Pharmacist Assessment Report
- Polysorbate 80: From Dry Eye Syndrome to Congenital Ichthyosiform Erythroderma
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Polysorbate 80: From Dry Eye Syndrome to Congenital Ichthyosiform Erythroderma
One-Sentence Summary
Polysorbate 80 is a nonionic surfactant and emulsifier, originally used in products for dry eye syndrome and xerophthalmia. The TxGNN model predicts it may be effective for congenital ichthyosiform erythroderma, but currently there are no clinical trials and no publications supporting this direction. The prediction rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Dry eye syndrome, xerophthalmia |
| Predicted New Indication | Congenital ichthyosiform erythroderma |
| TxGNN Prediction Score | 0.9943 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 1 of 1) |
| Number of DINs | 1 (marketed: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, polysorbate 80 is a nonionic surfactant and emulsifier. It is used in dry eye products as a lubricating and tear-film-stabilizing agent, and mechanistically it may be applicable to skin conditions involving a damaged barrier.
The link to the new indication is speculative. Congenital ichthyosiform erythroderma is a skin disorder with impaired barrier function and scaling. The emollient and surfactant properties of polysorbate 80 could, in theory, help with these features. This is a hypothesis only. Its wide use as a pharmaceutical excipient does not imply therapeutic efficacy in this disease. The only support for the prediction is the high TxGNN TxGNN model (deep learning) score, and no validated mechanism connects the drug to this condition.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02399148 | REFRESH OPTIVE ADVANCED | Not specified | Not specified |
Safety Considerations
Please refer to the package insert for safety information. No drug interaction records were found in the data compiled for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a model score (Evidence Level L5). There are no clinical trials or publications, and the mechanism of action is unknown. Polysorbate 80 is mainly an excipient, so there is currently no basis to advance it for congenital ichthyosiform erythroderma.
To proceed, the following is needed:
- Mechanism of action data for polysorbate 80, and a plausible link to the pathophysiology of ichthyosis
- Package insert warnings and contraindications from Health Canada (needed for safety screening)
- Preclinical or early clinical evidence in ichthyosis, such as skin barrier studies
- Assessment of route compatibility, since the current product is an ophthalmic formulation and a skin indication would likely need a topical one
- A literature and trial search targeted at surfactants or emollients in congenital ichthyosis
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.